SELLAS Life Sciences Group Inc buy DomRuinart
Start price
18.11.20
/
50%
€2.39
Target price
€4.00
Performance (%)
30.50%
End price
30.11.20
€3.12
Summary
This prediction ended on 30.11.20 with a price of €3.12. With a performance of 30.50% the BUY prediction by DomRuinart was a big success. DomRuinart has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
SELLAS Life Sciences Group Inc | -11.566% | -11.566% | -4.711% | -80.840% |
iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
According to DomRuinart what are the pros and cons of SELLAS Life Sciences Group Inc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by DomRuinart for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Buy mit Kursziel 4,0
In the thread Trading SELLAS Life Sciences Group Inc
Buy beendet